CalciMedica, Inc., a clinical-stage biotechnology company, focuses on developing therapies for life-threatening inflammatory diseases with unmet needs. Its proprietary technology targets the inhibition of calcium release-activated (CRAC) channels designs to modulate the immune response and protect against tissue cell injury in life-threatening inflammatory diseases. Its lead product candidate is Auxora, a proprietary intravenous-formulated CRAC channel inhibitor for the treatment of acute pancreatitis, asparaginase-associated acute pancreatitis, and acute kidney injury. The company is based in La Jolla, California.

CalciMedica, Inc.

CalciMedica is developing therapeutics that inhibit CRAC channels to address life-threatening inflammatory diseases affecting the pancreas, kidney, and lung.

CalciMedica

CalciMedica | 1,134 followers on LinkedIn. Leader in the development of CRAC channel inhibitor drugs for inflammatory diseases | CalciMedica is a privately held, clinical stage biotechnology company with a platform focused on CRAC channel drug discovery and development for the treatment of acute and severe inflammatory diseases. The Company was founded in 2007 by Ken Stauderman, CalciMedica’s Chief Scientific Officer, and colleagues at Torrey Pines Therapeutics in San Diego and Harvard’s Center for Blood Research in Cambridge, MA. Dr.

Frederic Guerard

Founder and Managing Director at Danforth Advisors

Daniel Geffken

Chief Regulatory Officer CalciMedica

Raven Jaeger

SVP, Clinical Development at CalciMedica

Andrew Cunningham

We are delighted to welcome Stephen Bardin to the CalciMedica team as Chief Financial Officer, and look forward to working together as we continue to advance our clinical-stage pipeline. Read the press release: https://lnkd.in/excRjSrX

We are excited to be presenting the full data set from our Phase 2b CARPO trial of Auxora in #acutepancreatitis on a conference call and webcast, during which Prof. Robert Sutton will deliver his plenary presentation from the American College of Gastroenterology (ACG) Annual Scientific Meeting. See our press release for a description of the late-breaking, positive data, including a win ratio analysis, and for instructions to join the webcast: https://lnkd.in/eqDePnKK

We are pleased to announce a late-breaking abstract for a plenary presentation by Prof. Robert Sutton from the University of Liverpool at American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting. Details in the press release: https://lnkd.in/egniHv87 #ACG2024

Earlier this week we shared the news that the first patient has been dosed in #KOURAGE , our Phase 2 trial evaluating Auxora for the treatment of severe acute kidney injury with associated acute hypoxemic respiratory failure (AHRF). There are currently no approved therapies for AKI and we look forward to continuing to evaluate Auxora as a potential treatment for this severe and underserved disease. See our press release: https://lnkd.in/e8HzWKjJ

Today we announced that the first patient has been dosed in #KOURAGE , our Phase 2 trial evaluating Auxora for the treatment of severe #acutekidneyinjury with associated acute hypoxemic respiratory failure (AHRF). We expect to share topline data from this trial in 2025. Read the press release: https://lnkd.in/eRmNxsik

We are excited to share that today we announced positive topline data from our Phase 2b CARPO trial of #Auxora in #acutepancreatitis (AP). The trial established a dose response for Auxora across multiple endpoints, identified both the target patient population and the likely drug dose for a pivotal trial, and re-affirmed Auxora’s safety profile and tolerability as seen in prior clinical trials. Read the press release: https://lnkd.in/gAgBCaAW

We recently completed enrollment in our ongoing Phase 2b clinical trial, CARPO, which is evaluating Auxora™ in patients with #acutepancreatitis with accompanying SIRS. For details on the clinical trial, visit https://lnkd.in/eTwrEFCa , or hear some of our study investigators discuss the potential for #Auxora to improve outcomes for patients with AP.

Today we announced that the last patient has been enrolled in our Phase 2b CARPO trial of Auxora™ in #acutepancreatitis (AP). Details here: https://lnkd.in/eqjarCww

Today CalciMedica reported financial results for the year ended December 31, 2023. Read the press release here: https://lnkd.in/eEFNhNSK

Yesteday we presented data from preclinical studies of Auxora in acute kidney injury at the 29th International AKI & CRRT Conference. The data show that Auxora hastens recovery of kidney function and improves survival in a rat model of #AKI . https://lnkd.in/g5h4vxbY

	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
net income	-28.38M -	-37.04M 30.51%	-27.53M 25.67%	-35.82M 30.11%	-35.60M 0.60%	-34.36M 3.51%
depreciation and amortization	175K -	303K 73.14%	395K 30.36%	519K 31.39%	338K 34.87%	58K 82.84%
deferred income tax		-68K -	1K 101.47%		1.38M -	-3.31M 340.60%
stock based compensation	348K -	738K 112.07%	1.79M 142.28%	5.38M 200.62%	6.71M 24.89%	12.04M 79.34%
change in working capital	-379K -	4.92M 1,398.42%	-4.56M 192.64%	-1.63M 64.22%	1.83M 212.02%	-267K 114.61%
accounts receivables
inventory
accounts payables	1.37M -	1.40M 2.41%	-1.46M 204.21%	-2.05M 40.36%	1.30M 163.55%	-1.43M 209.43%
other working capital	-1.75M -	3.52M 301.14%	-3.10M 188.03%	421K 113.59%	523K 24.23%	1.16M 121.80%
other non cash items	18K -	-72K 500%	-2.16M 2,897.22%	58K 102.69%	2.47M 4,160.34%	110K 95.55%
net cash provided by operating activities	-28.22M -	-31.21M 10.63%	-32.06M 2.72%	-31.50M 1.76%	-22.88M 27.37%	-25.73M 12.46%
investments in property plant and equipment	-1.46M -	-605K 58.59%	-1.02M 69.09%	-488K 52.30%	-2.25M 361.48%	-78K 96.54%
acquisitions net					1.94M -
purchases of investments		-22.52M -	-61.64M 173.76%	-94.57M 53.43%	-35.57M 62.39%	-6.12M 82.80%
sales maturities of investments		2.50M -	20.10M 704%	105.81M 426.41%	64.35M 39.18%	15.08M 76.57%
other investing activites					-1.51M -
net cash used for investing activites	-1.46M -	-20.62M 1,311.36%	-42.56M 106.40%	10.75M 125.26%	26.96M 150.75%	8.88M 67.05%
debt repayment
common stock issued			96.25M -			25.45M -
common stock repurchased
dividends paid
other financing activites	42.02M -	54.87M 30.59%	-4.08M 107.44%	695K 117.02%	-139K 120%	-4.54M 3,169.78%
net cash used provided by financing activities	42.02M -	54.87M 30.59%	92.17M 67.98%	695K 99.25%	-139K 120%	20.90M 15,135.97%
effect of forex changes on cash
net change in cash	12.34M -	3.04M 75.40%	17.55M 478.00%	-20.05M 214.28%	3.94M 119.65%	4.05M 2.89%
cash at beginning of period	492K -	12.83M 2,508.54%	15.87M 23.66%	33.42M 110.57%	13.36M 60.01%	1.48M 88.96%
cash at end of period	12.83M -	15.87M 23.66%	33.42M 110.57%	13.36M 60.01%	17.30M 29.48%	5.53M 68.04%
operating cash flow	-28.22M -	-31.21M 10.63%	-32.06M 2.72%	-31.50M 1.76%	-22.88M 27.37%	-25.73M 12.46%
capital expenditure	-1.46M -	-605K 58.59%	-1.02M 69.09%	-488K 52.30%	-2.25M 361.48%	-78K 96.54%
free cash flow	-29.68M -	-31.82M 7.22%	-33.09M 3.98%	-31.99M 3.32%	-25.13M 21.44%	-25.81M 2.69%

COM:CALCIMEDICA

CalciMedica

Last Close

3.45

22/11 21:00

Market Cap

49.23M

Beta: -

Volume Today

27.23K

Avg: -

Preview